Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease
The Disrupt CAD III Study

Dean J. Kereiakes, MD

The Christ Hospital Heart and Vascular Center

Carl and Edyth Lindner Center for Research and Education

Cincinnati, OH

Jonathan Hill, MD, Richard Shlofmitz, MD, Andrew Klein, MD, Robert Riley, MD, Matthew Price, MD, Howard Herrmann, MD, William Bachinsky, MD, Ron Waksman, MD, Gregg W. Stone, MD

TCT CONNECT
CRF

Disclosure Statement of Financial Interest

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

| Affiliation/Financial Relationship	Company
Modest Consulting Fees	SINO Medical Sciences Technologies Inc.,
Significant Consulting Fees	Boston Scientific Corporation
Significant Consulting Fees	Elixir Medical Inc.,
Significant Consulting Fees	Svelte Medical Systems Inc.,
Significant Consulting Fees	Caliber Therapeutics/ Orchestra Biomed
Significant Consulting Fees	Shockwave Medical Inc.,
Major Stock Shareholder/Equity	Ablative Solutions Inc.,

# Coronary Calcification Impacts PCI


Impairs device crossing

Delamination

Under expansion

Balloon:
Insufficient force

Atheroablative technologies
Atherectomy: Wire bias

Laser: Unpredictable

# Acoustic Pressure Waves Fracture Calcium

Acoustic pressure waves (1 pulse/sec) travel through tissue with an effective pressure of **~50 atm and fractures both superficial and deep calcium**

Disrupt CAD III: Study Design*

Prospective, multicenter, single-arm global IDE
NCT03595176

Heavily calcified†, *de novo* coronary lesions
RVD 2.5-4.0 mm, stenosis ≥50%, lesion length ≤40mm
One roll-in patient per site allowed
47 global sites

Roll-in Population
N = 47

ITT Population
N= 384

OCT Sub-study
N= 100

Richard Shlofmitz, MD
TCT 2020

30-day Follow-up

1-year Follow-up

2-year Follow-up

*Kereiakes et al., *Am Heart J* 2020;225:10-18.
†Radio-opacities both sides of vessel ≥15 mm length by angiography or calcium angle ≥270° by OCT or IVUS

Major Endpoints

- **Primary safety endpoint:** Freedom from MACE at 30 days
  - Cardiac death, or
  - Myocardial infarction*, or
  - Target vessel revascularization

- **Primary effectiveness endpoint:** Procedural success
  - Successful stent delivery with residual stenosis <50% and without in-hospital MACE

- **Secondary endpoints:**
  - Device crossing success[†]
  - Angiographic success[‡]
  - Procedural success with residual stenosis ≤30% and without in-hospital MACE
  - Sensitivity analysis for peri-procedural MI using the SCAI and 4th Universal Definitions[§]

*CK-MB level >3x ULN through discharge (peri-procedural MI) and using the 4th Universal Definition of MI beyond discharge
[†]Delivery of IVL across the target lesion and delivery of lithotripsy without serious angiographic complications immediately after IVL
[‡]Stent delivery with < 50% or ≤ 30% residual stenosis and without serious angiographic complications at any time during the procedure
[§]Moussa et al., *J Am Coll Cardiol* 2013;62:1563-70; Thygesen et al., *J Am Coll Cardiol* 2018;72:2231-64.

Key Clinical and Angiographic Eligibility Criteria

Inclusion

- Biomarkers (troponin or CK-MB) normal within 12 hours prior to procedure

- LVEF >25% within 6 months of procedure

- Single *de novo* target lesion with stenosis ≥70% and <100% or ≥50% and <70% with evidence of ischemia, or FFR ≤0.80, or lumen area ≤4.0 mm^2 by IVUS or OCT

- Target vessel RVD ≥2.5 mm and ≤4.0 mm

- Lesion length ≤40 mm

- Lesion site severe calcification:
  - Angiographic radio-opacities prior to contrast involving both sides of arterial wall with total calcium length ≥15 mm, or presence of ≥270° of calcium on at least one cross section by IVUS or OCT

Exclusion

- Renal failure (serum creatinine >2.5 or chronic dialysis)

- Acute MI within 30 days prior to index procedure

Statistical Methods

- Pre-specified performance goals (PG) were based on the rates from the predicate single-arm, non-randomized ORBIT II IDE study[*]:
  - Enrolled similar patient population with similar endpoints and definitions
  - Relative risk of 1.5 was utilized
- Primary safety performance goal: 84.4%
  - Calculation: 100% - (1.5 * observed 30-day MACE rate in ORBIT II of 10.4%)
- Primary effectiveness performance goal: 83.4%
  - Calculation: 100% - (1.5 * observed procedural failure rate in ORBIT II of 11.1%)
- Power ≈ 81% for <u>both</u> co-primary PGs at a 1-sided type 1 error rate of 5%
  - Expected freedom from MACE at 30-days = 89.6% power
  - Expected procedural success rate = 88.9% power
  - N = 392 evaluable patients with expected rate of attrition = 5%

[*]Chambers et al., *JACC Cardiovasc Interv*. 2014;7(5): 510-518
Kereiakes et al., *Am Heart J* 2020;225:10-18

Disrupt CAD III: Top Enrolling Centers

1. Richard Shlofmitz
   St. Francis Hospital

2. Andrew Klein
   Piedmont Heart Institute

3. Robert Riley
   The Christ Hospital

4. Matthew Price
   Scripps Clinic

5. Howard Herrmann
   University of Pennsylvania

6. William Bachinsky
   UPMC Pinnacle Health

6. Ron Waksman
   MedStar Washington Hospital Center

8. Barry Bertolet
   North Mississippi Medical Center

9. John Wang
   MedStar Union Memorial Hospital

10. Jean Fajadet
    Clinique Pasteur

10. Alpesh Shah
    Houston Methodist Hospital

12. Sarang Mangalmurti
    Bryn Mawr Hospital

13. Robert Stoler
    Baylor Heart and Vascular Hospital

13. Janusz Lipiecki
    Clinique des Domes

Study Flow and Follow-up

Baseline Clinical Characteristics

Characteristic	N=384
Age	71.2 ± 8.6
Male	76%
Hypertension	89%
Hyperlipidemia	89%
Diabetes mellitus	40%
Current smoker	12%
Prior MI	18%
Prior CABG	9%
Prior Stroke	8%
Renal insufficiency*	26%

Angina Class

Class	Percentage
0	13%
I	15%
II	37%
III	33%
IV	2%

*Defined as eGFR <60ml/min/1.73m^2; eGFR=estimated glomerular filtration rate using the MDRD formula

Angiographic Characteristics

Core Lab Analysis		N=384
Target vessel	LAD	56.5%
	LCx	12.8%
	RCA	29.2%
	LM	1.6%
Reference vessel diameter, mm		3.0 ± 0.5
Minimum lumen diameter, mm		1.1 ± 0.4
Diameter stenosis		65.1 ± 10.8%
Lesion length, mm		26.0 ± 11.7
Calcified length, mm		47.9 ± 18.8
Severe calcification		100%

Procedural Characteristics

Characteristic	N=384
Total procedure time, min	59.0 ± 29.6
Pre-dilatation	55.2%
IVL catheters	1.2 ± 0.5
IVL pulses	68.8 ± 31.9
Max IVL inflation pressure, atm	6.0 ± 0.3
Post-IVL dilatation	20.7%
Number of stents	1.3 ± 0.5
Stent delivery	99.2%
Post-stent dilatation	99.0%

Angiographic Outcomes

Diameter Stenosis* — bar chart showing Pre-procedure 65.1%, Post-IVL 37.2%, Final In-stent 11.9%

Cumulative Frequency Shift — cumulative frequency (%) vs minimum lumen diameter (mm) for Pre-procedure, Post-IVL, and Post-stent

*Final in-stent diameter stenosis ≤30% achieved in 99.5% of patients

Angiographic Complications

Core Lab Analysis	Immediately Post-IVL	Final Post-stent
Any serious angiographic complication	2.6%	0.5%
Severe dissection (Type D-F)	2.1%	0.3%
Perforation	0.0%	0.3%
Abrupt closure	0.0%	0.3%
Slow flow	0.6%	0.0%
No-reflow	0.0%	0.0%

In-hospital and 30-day MACE

*Per protocol: CK-MB level >3x ULN at discharge (peri-procedural MI) and using the 4th Universal Definition of MI beyond discharge

Secondary Endpoints

Composite Success Rates

Bar chart showing Event Rate (%) on the y-axis from 0% to 100%:

- Device Crossing Success[*]: 95.8%
- Angiographic Success w/RS < 50%[†]: 96.4%
- Angiographic Success w/RS ≤ 30%[†]: 96.1%
- Procedural Success w/RS ≤ 30%[‡]: 92.2%

[*]Delivery of IVL across the target lesion and delivery of lithotripsy without serious angiographic complications immediately after IVL
[†]Stent delivery with < 50% or ≤ 30% residual stenosis and without serious angiographic complications at any time during the procedure
[‡]Successful stent delivery with residual stenosis < 50% and without in-hospital MACE

Secondary Endpoints

Periprocedural MI

Event Rate (%)

- Per Protocol Definition[*]: 6.8%
- 4th Universal Definition[§]: 7.3%
- SCAI Definition[†]: 2.6%

At 30 days

Event Rate (%)

- Target lesion failure: 7.6%
- All revascularization: 2.6%
- Stent thrombosis: 0.8%

[*]CK-MB level >3x ULN at discharge (peri-procedural MI) and using the 4th Universal Definition of MI beyond discharge
[†]Moussa et al., *J Am Coll Cardiol* 2013. 62:1563-70;
[§]Thygesen et al., *J Am Coll Cardiol* 2018. 72:2231-64.

IVL-induced Ventricular Capture[*]

	No IVL-induced capture (N=245)	IVL-induced capture (N=171)	*P* value
Pre-procedure heart rate, bpm	69.0 ± 11.9	65.9 ± 11.4	0.009
Drop in systolic BP during procedure	24.5%	40.5%	0.0007
Magnitude of systolic BP decrease, mmHg	23.5 ± 15.0	18.9 ± 14.2	0.07
Sustained ventricular arrhythmia during or immediately after IVL procedure	0.4%	0.0%	1.0

[*]41% of patients with no sustained ventricular arrhythmias or clinical sequalae

Conclusions

- Disrupt CAD III trial success was achieved as both primary safety and effectiveness endpoints were met following treatment with coronary IVL in severely calcified lesions

- Coronary IVL prior to DES implantation was well tolerated with a low rate of major peri-procedural clinical and angiographic complications

- Transient IVL-induced ventricular capture was common, but was benign with no clinical sequelae in any patient

- Although this study represents the initial coronary IVL experience for U.S. operators, high procedural success and low angiographic complications were achieved, reflecting the relative ease of use of IVL technology

Journal Pre-proof

Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease

Jonathan M. Hill, MD, Dean J. Kereiakes, MD, Richard A. Shlofmitz, MD, Andrew J. Klein, MD, Robert F. Riley, MD, Matthew J. Price, MD, Howard C. Herrmann, MD, William Bachinsky, MD, Ron Waksman, MD, Gregg W. Stone, MD

PII: S0735-1097(20)37398-8

DOI: https://doi.org/10.1016/j.jacc.2020.09.603

Reference: JAC 27787

To appear in: Journal of the American College of Cardiology

Special thanks to the Disrupt CAD III sites and patients and the clinical research group!

Back-Up

Primary Safety by Sub-groups

Sub-group	Freedom from 30-day MACE	Difference (95% CI)	*P* value
Age ≤ 71[*]	92.0%	0.4 (-5.5, 6.3)	1.0
Age > 71	92.4%		
Male	93.8%	-2.8 (-10.4, 4.8)	0.38
Female	90.0%		
U.S.	91.6%	4.3 (-3.2, 11.8)	0.40
EU	95.9%		
Diabetes	91.1%	1.6 (-4.8, 8.0)	0.56
No diabetes	92.7%		
Renal insufficiency[†]	90.1%	3.1 (-4.1, 10.3)	0.38
No renal insufficiency	93.2%		
Prior CABG	94.3%	-2.3 (-12.1, 7.4)	1.0
No prior CABG	92.0%		
RVD ≤ 3.0 mm[*]	91.8%	0.6 (-5.3, 6.6)	0.85
RVD > 3.0 mm	92.4%		
Lesion length ≤ 25 mm[*]	94.2%	-4.3 (-10.2, 1.6)	0.13
Lesion length > 25 mm	90.0%		
Bifurcated lesions	88.6%	5.1 (-2.1, 12.2)	0.10
No bifurcated lesion	93.7%		

Difference (95% CI): -15 -10 -5 0 5 10 15

[*]Subgroup based on median value

[†]Defined as eGFR < 60ml/min/1.73m^2 as calculated using the MDRD formula

Primary Effectiveness by Sub-groups

| Sub-group	Procedural Success		Difference (95% CI)	P value
Age ≤ 71*	92.5%		0.3 (-5.8, 5.8)	1.0
Age > 71	92.4%			
Male	93.2%		-3.2 (-10.8, 4.4)	0.36
Female	90.0%			
U.S.	91.6%		6.3 (-1.5, 14.3)	0.15
EU	98.0%			
Diabetes	92.6%		-0.3 (-6.4, 5.7)	1.0
No diabetes	92.3%			
Renal insufficiency†	90.1%		3.5 (-3.6, 10.7)	0.27
No renal insufficiency	93.6%			
Prior CABG	94.4%		-2.2 (-11.7, 7.3)	1.0
No prior CABG	92.3%			
RVD ≤ 3.0 mm*	91.8%		1.1 (-4.7, 7.0)	0.70
RVD > 3.0 mm	93.0%			
Lesion length ≤ 25 mm*	94.3%		-3.8 (-9.6, 2.1)	0.18
Lesion length > 25 mm	90.5%			
Bifurcated lesions	89.6%		4.1 (-2.8, 11.0)	0.20
No bifurcated lesion	93.7%			

Difference (95% CI)

-15 -10 -5 0 5 10 15

*Subgroup based on median value
†Defined as eGFR < 60ml/min/1.73m^2 as calculated using the MDRD formula